Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Subscribe To Our Newsletter & Stay Updated
